Cargando…

Ketamine for Bipolar Depression: Biochemical, Psychotherapeutic, and Psychedelic Approaches

Bipolar disorder (type 1) is a serious and chronic psychiatric illness that can be difficult to treat. Many bipolar patients have refractory depressive episodes. Racemic ketamine, a glutamate modulator with prominent dissociate and psychedelic properties, has been demonstrated to have rapid acting a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bennett, Raquel, Yavorsky, Christian, Bravo, Gary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289960/
https://www.ncbi.nlm.nih.gov/pubmed/35859608
http://dx.doi.org/10.3389/fpsyt.2022.867484
_version_ 1784748781810483200
author Bennett, Raquel
Yavorsky, Christian
Bravo, Gary
author_facet Bennett, Raquel
Yavorsky, Christian
Bravo, Gary
author_sort Bennett, Raquel
collection PubMed
description Bipolar disorder (type 1) is a serious and chronic psychiatric illness that can be difficult to treat. Many bipolar patients have refractory depressive episodes. Racemic ketamine, a glutamate modulator with prominent dissociate and psychedelic properties, has been demonstrated to have rapid acting antidepressant and anti-obsessional effects which may be useful for treating the symptoms of bipolar depression. Most of the existing research literature on unipolar and bipolar depression has looked at racemic ketamine in the sub-psychedelic dose range given by infusion as a stand-alone treatment (without concurrent psychotherapy). This article expands on the existing research by articulating three different paradigms for ketamine treatment: biochemical, psychotherapeutic, and psychedelic. The authors use composite clinical vignettes to illustrate different ways of working with ketamine to treat bipolar depression, and discuss a variety of clinical considerations for using ketamine with this population, including route, dose, frequency, chemical mitigators, and adverse events. Note that the conceptual paradigms could be applied to any ketamine treatment, with broad applicability beyond bipolar treatment.
format Online
Article
Text
id pubmed-9289960
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92899602022-07-19 Ketamine for Bipolar Depression: Biochemical, Psychotherapeutic, and Psychedelic Approaches Bennett, Raquel Yavorsky, Christian Bravo, Gary Front Psychiatry Psychiatry Bipolar disorder (type 1) is a serious and chronic psychiatric illness that can be difficult to treat. Many bipolar patients have refractory depressive episodes. Racemic ketamine, a glutamate modulator with prominent dissociate and psychedelic properties, has been demonstrated to have rapid acting antidepressant and anti-obsessional effects which may be useful for treating the symptoms of bipolar depression. Most of the existing research literature on unipolar and bipolar depression has looked at racemic ketamine in the sub-psychedelic dose range given by infusion as a stand-alone treatment (without concurrent psychotherapy). This article expands on the existing research by articulating three different paradigms for ketamine treatment: biochemical, psychotherapeutic, and psychedelic. The authors use composite clinical vignettes to illustrate different ways of working with ketamine to treat bipolar depression, and discuss a variety of clinical considerations for using ketamine with this population, including route, dose, frequency, chemical mitigators, and adverse events. Note that the conceptual paradigms could be applied to any ketamine treatment, with broad applicability beyond bipolar treatment. Frontiers Media S.A. 2022-05-23 /pmc/articles/PMC9289960/ /pubmed/35859608 http://dx.doi.org/10.3389/fpsyt.2022.867484 Text en Copyright © 2022 Bennett, Yavorsky and Bravo. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Psychiatry
Bennett, Raquel
Yavorsky, Christian
Bravo, Gary
Ketamine for Bipolar Depression: Biochemical, Psychotherapeutic, and Psychedelic Approaches
title Ketamine for Bipolar Depression: Biochemical, Psychotherapeutic, and Psychedelic Approaches
title_full Ketamine for Bipolar Depression: Biochemical, Psychotherapeutic, and Psychedelic Approaches
title_fullStr Ketamine for Bipolar Depression: Biochemical, Psychotherapeutic, and Psychedelic Approaches
title_full_unstemmed Ketamine for Bipolar Depression: Biochemical, Psychotherapeutic, and Psychedelic Approaches
title_short Ketamine for Bipolar Depression: Biochemical, Psychotherapeutic, and Psychedelic Approaches
title_sort ketamine for bipolar depression: biochemical, psychotherapeutic, and psychedelic approaches
topic Psychiatry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289960/
https://www.ncbi.nlm.nih.gov/pubmed/35859608
http://dx.doi.org/10.3389/fpsyt.2022.867484
work_keys_str_mv AT bennettraquel ketamineforbipolardepressionbiochemicalpsychotherapeuticandpsychedelicapproaches
AT yavorskychristian ketamineforbipolardepressionbiochemicalpsychotherapeuticandpsychedelicapproaches
AT bravogary ketamineforbipolardepressionbiochemicalpsychotherapeuticandpsychedelicapproaches